K2 medical research

Maitland, Florida 32751

10 studies enrolling now · 31 studies all time

What they study most

Agitation Associated With Alzheimer's Dementia, Alcohol Use Disorder, Alzheimer Disease, Alzheimer's Disease, Alzheimer's Disease, Early Onset, Anhedonia, Brain Diseases, Central Nervous System Diseases, Cognitive Dysfunction, Dementia, Depressive Disorder, Major, Early Alzheimers Disease

Studies at this site

• Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures — Recruiting now
• A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease — Recruiting now
• A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia — Recruiting now
• A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity — Recruiting now
• LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis — Recruiting now
• Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease — Recruiting now
• A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD) — Recruiting now
• [18F]PI-2620 Phase 3 Histopathological Study — Recruiting now
• Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia — Recruiting now
• A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder — Running, not enrolling
• A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder — Completed
• Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND) — Enrolling by invitation
• A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6) — Running, not enrolling
• A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease — Completed
• A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1) — Completed
• A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD — Running, not enrolling
• A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone — Completed
• To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications — Running, not enrolling
• A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease — Stopped early
• A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder — Completed
• 53-Week Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 With Mild to Severe Tibio-Femoral Osteoarthritis of the Knee — Running, not enrolling
• A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy — Completed
• A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3) — Running, not enrolling
• A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease — Completed
• Gene Therapy for APOE4 Homozygote of Alzheimer's Disease — Completed
• Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease — Stopped early
• A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age — Completed
• Study of ASN51 in Adults With Early Alzheimer's Disease — Stopped early
• A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD — Completed
• A Phase 1 Study of VG-3927 in Healthy Adults and Patients With Alzheimer's Disease — Completed
• Identification of Patients With a High Probability of Meeting Eligibility Criteria for an Alzheimer's Disease Clinical Trial (APHELEIA) — Completed